Maternal & Neonatal Benefits of Prophylactic Administration of Vitamin K

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Vitamin K deficiency can cause serious risks to pregnant women and their babies that may lead to hemorrhage, especially in newborns. We aim to evaluate the efficacy of vitamin k in decreasing blood loss during and after elective cesarean section (CS), and to assess the neonatal beneficial effects of prophylactic maternal vitamin k administration.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04676958` - viTAmin K2 and rEcOVery From ExeRcise	N/A

NCT number	NCT04984083
Study type	Interventional
Source	National Research Centre, Egypt
Contact
Status	Completed
Phase	N/A
Start date	July 30, 2021
Completion date	December 31, 2021

Maternal and Neonatal Benefits of Prophylactic Administration of Vitamin K Before Elective Cesarean Section

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms